We are live on ! Find out more
TLSIW icon

TriSalus Life Sciences Warrant
TLSIW

7 hedge funds and large institutions have $1.23M invested in TriSalus Life Sciences Warrant in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% less funds holding

Funds holding: 8 → 7 (-1)

30% less capital invested

Capital invested by funds: $1.77M → $1.23M (-$537K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
7
Holders Change
-1
Holders Change %
-12.5%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$741
2
Rockefeller Capital Management
Rockefeller Capital Management
New York
+$67

Top Sellers

Rank Fund Capital Flow
1
WAM
Wolverine Asset Management
Illinois
-$51.4K
2
Citadel Advisors
Citadel Advisors
Florida
-$17.6K
3
Bank of America
Bank of America
North Carolina
-$1.68K
4
FBCM
Fort Baker Capital Management
California
-$135

TLSIW Hedge Fund Activity: Q1 2026 in Review

7 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences Warrant (TLSIW) for Q1 2026, worth a combined $1.23M — down 30% from $1.77M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of TLSIW and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.

The largest buyer was Aristeia Capital, adding an estimated $741. The largest seller was Wolverine Asset Management, exiting entirely with an estimated $51.4K sold.

  • 7 institutional investors held TriSalus Life Sciences Warrant (TLSIW) as of Q1 2026, down from 8 in Q4 2025.
  • Funds reported $1.23M of TriSalus Life Sciences Warrant stock for Q1 2026, down 30% quarter-over-quarter.
  • 1 fund opened new TriSalus Life Sciences Warrant positions in Q1 2026 and 2 closed out, a net change of -1 holder.
  • The largest TriSalus Life Sciences Warrant buyer in Q1 2026 was Aristeia Capital, an estimated $741 added.
  • The largest TriSalus Life Sciences Warrant seller in Q1 2026 was Wolverine Asset Management, an estimated $51.4K sold.

Based on aggregated 13F filings for Q1 2026.